- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
California Health Care Cuts Will Cripple Prevention, Leave Poor Out In Cold, Counties Say
A battle has broken out between California counties and Governor Jerry Brown, who is proposing to take an estimated $2.5 billion over the next three years from local health and prevention programs.
These funds, which have flowed from the state to counties since 1991, support community clinics in Los Angeles and other cities that serve poor people who don’t have insurance. They help pay for public health programs, like one in Alameda County that provides preventive services to children with asthma, reducing hospitalizations.
The Brown administration says the money will no longer be needed by the counties because the Affordable Care Act—Obamacare—will enable low-income people to obtain health coverage, either through the Medicaid program or from federal subsidies for private health insurance. Brown proposes to take $300 million from the counties this fiscal year, $900 million next year and $1.3 billion in 2015-2016.
Read the full story here: http://onforb.es/13hkXpU
Source: Forbes
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
